Given the mechanism of action, a new phase I study of AFM13 in combination with cord-blood-derived, cytokine-preactivated allogeneic NK cells has shown impressive efficacy in relapsed/refractory CD30+ lymphoma [202]. This evidence concerns the gene TNFRSF8 and lymphoma.